Government-Owned Inventions; Availability for Licensing, 8705-8707 [E8-2752]
Download as PDF
<![CDATA[
rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 73, No. 31 / Thursday, February 14, 2008 / Notices
Proteins or other biologically active
molecules are easily denatured, and
once introduced into the body, rapidly
cleared. These problems are
circumvented by first incorporating the
protein into the microbead. Microbeads
with protein payloads are then
introduced into the tissue of interest,
where the microbeads remain while
degrading into biologically innocuous
materials while delivering the protein/
drug payload for adjustable periods of
time ranging from hours to weeks. This
technology is an improvement of the
microbead technology described in U.S.
Patent No. 5,759,582.
Applications: This technology has
two commercial applications. The first
is a pharmaceutical drug delivery
application. The bead allows the
incorporated protein or drug to be
delivered locally at high concentration,
ensuring that therapeutic levels are
reached at the target site while reducing
side effects by keeping systemic
concentration low. The microbead
accomplishes this while protecting the
biologically active protein from harsh
conditions traditionally encountered
during microbead formation/drug
formulation.
The microbeads are inert,
biodegradable, and allow a sustained
release or multiple-release profile of
treatment with various active agents
without major side effects. In addition,
the bead maintains functionality under
physiological conditions.
Second, the microbeads and
microparticles can be used in various
research assays, such as isolation and
separation assays, to bind target proteins
from biological samples. A disadvantage
of the conventional methods is that the
proteins become denatured. The
denaturation results in incorrect binding
studies or inappropriate binding
complexes being formed. The instant
technology corrects this disadvantage by
using a bead created in a more neutral
pH environment. It is this same
environment that is used for the binding
of the protein of interest as well.
Inventor: Phillip F. Heller (NIA).
Patent Status:
U.S. Provisional Application No. 60/
602,651 filed 19 Aug 2004 (HHS
Reference No. E–116–2004/0–US–01)
PCT Application No. PCT/US2005/
026257 filed 25 Jul 2005, which
published as WO 2006/023207 on 02
Mar 2006 (HHS Reference No. E–116–
2004/0–PCT–02)
U.S. Patent Application No. 11/659,976
filed 12 Feb 2007 (HHS Reference No.
E–116–2004/0–US–03)
Licensing Status: Available for nonexclusive or exclusive licensing.
VerDate Aug<31>2005
16:49 Feb 13, 2008
Jkt 214001
Licensing Contact: Susan O. Ano,
PhD; 301/435–5515; anos@mail.nih.gov.
Dated: February 7, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–2749 Filed 2–13–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
New Inhibitors of Multidrug Resistant
Proteins Such as ABCG2
Description of Technology: Drug
resistance plays a significant role in the
failure of cancer chemotherapy. Some
proteins such as ABCG2, Pgp and MRP1
that belong to the superfamily of ATPbinding cassette transporters contribute
to this process.
Two categories of ABCG2 protein
inhibitors—botryllamides, isolated from
a marine sponge, and naphthopyrones,
isolated from marine sea stars—have
been obtained by high-throughput
screening of 89,000 natural product
extracts from the Natural Products
Repository at NCI.
These new compounds serve as
potential therapeutic agents for cancer
chemotherapy either exclusively or in
combination with conventional
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
8705
regimens. The study of structure-activity
relationships will help delineate
features that would enhance activity
and specificity to multiple drug
resistant proteins.
Advantages: Increase bioavailability
of orally administered drugs; Enhance
drug delivery to certain tissues.
Applications: Cancer therapeutics;
Cancer stem cell research; Study of
structure, function and relevance of
MDR in cancer.
Market: Cancer is the second leading
cause of death in America, after heart
disease. Multiple drug resistance is a
significant impediment in the treatment
of cancers resulting in poor prognosis.
Some cancers with demonstrated high
levels of MDR are leukemia, colon,
renal, liver, adrenocortical, and
pancreatic. Breast, ovarian, sarcoma and
small-cell lung cancer show increased
MDR on treatment.
This new technology has the potential
to increase the effectiveness of
conventional chemotherapy and
prognosis of cancer.
Developmental Status: Early stage.
Inventors: Curtis J. Henrich et al.
(NCI).
Patent Status: U.S. Provisional
Application No. 60/018,758 filed 03 Jan
2008 (HHS Reference No. E–315–2007/
0–US–01).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: John Stansberry,
PhD; 301/435–5236;
stansbej@mail.nih.gov.
TGF-b Gene Expression Signature in
Cancer Prognosis
Description of Technology:
Hepatocellular carcinoma (HCC) is the
third leading cause of cancer death
worldwide, and it is very heterogeneous
in terms of its clinical presentation as
well as genomic and transcriptomic
patterns. This heterogeneity and the
lack of appropriate biomarkers have
hampered patient prognosis and
treatment stratification.
Available for licensing is a novel
temporal TGF-b gene expression
signature that predicts HCC patient
clinical outcomes. Patients with tumors
expressing late TGF-b responsive genes
had a malignant prognosis and an
invasive tumor phenotype as evaluated
by decreased survival time, increased
tumor recurrence, and vascular invasion
rate. Additionally, this signature may
also be able to prognose other cancers,
including lung cancer.
Applications: Method to diagnose
cancer; Method to monitor cancer
progression and aid clinicians to choose
appropriate therapies; Commercial kits
to prognose cancer.
E:\FR\FM\14FEN1.SGM
14FEN1
8706
Federal Register / Vol. 73, No. 31 / Thursday, February 14, 2008 / Notices
Advantages: Early diagnostic tool to
stratify HCC patients to chose more
effective treatment.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Market:
An estimated 1,444,920 new cancer
diagnoses in the U.S. in 2007.
Cancer is the second leading cause of
death in United States.
It is estimated that the cancer
therapeutic market would double to $50
billion a year in 2010 from $25 billion
in 2006.
Inventors: Snorri Thorgeirsson (NCI)
and Cedric Coulouaran (NCI).
Relevant Publication: Manuscript in
press Hepatology 2008.
Patent Status: U.S. Provisional
Application No. 60/981,661 filed 22 Oct
2007 (HHS Reference No. E–282–2007/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Jennifer Wong;
301–435–4633; wongje@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute, Center for
Cancer Research, Laboratory of
Experimental Carcinogenesis is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize a novel temporal TGF-b
gene expression signature that predicts
HCC patient clinical outcomes. Please
contact John D. Hewes, PhD at 301–435–
3121 or hewesj@mail.nih.gov for more
information.
rwilkins on PROD1PC63 with NOTICES
A Fold-Back Diabody Format for
Diphtheria Toxin-Based Immunotoxins
That Can Increase Binding and Potency
Description of Technology: NIH
inventors, in collaboration with Scott
and White Memorial Hospital inventors,
have developed new immunotoxins
comprising a mutant diphtheria toxin
linked to an anti-prostate specific
membrane antigen (PSMA) fold-back
diabody. The fold-back diabody
construct has a shortened linker region
between the heavy and light chains of
the antibody variable domain. This
construct allows interactions between
the longer-linked variable domains
while preventing interactions between
the shorter-linked variable domains.
This results in increased efficiency of
epitope recognition and delivery to the
appropriate target cells. These
immunotoxins can be used for the
treatment of cancers that overexpress
PMSA, with specific application against
prostate cancer.
Applications:
Treatment of primary prostate tumors.
VerDate Aug<31>2005
16:49 Feb 13, 2008
Jkt 214001
Treatment of metastatic prostate
tumors, for which no currently effective
treatment exists.
Application against other tumors
expressing the PSMA epitope on the
tumor neovasculature such as breast
cancer.
Advantages:
Increased potency of 10–40-fold
resulting from the use of the fold-back
diabody construct.
First treatment with applications to
metastatic prostate cancer.
Pichia pastoris production process of
the fold-back immunotoxin can be used
to scale up for GMP production.
Benefits:
Significant social benefit for
successfully treating the second leading
cause of cancer-related deaths among
males in the United States.
Approximately 8 billion USD per year
are spent on prostate cancer treatment;
a new treatment could procure a
significant financial position.
Opportunity to occupy a strong
market position through the
development of the first treatment of
metastatic prostate cancer.
Inventors: David Neville (NIMH) et al.
Patent Status: U.S. Patent Application
No. 60/953,416 filed 01 Aug 2007 (HHS
Reference No. E–268–2007/0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: David A.
Lambertson, PhD; 301–435–4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Mental Health,
Laboratory of Molecular Biology, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
anti-PSMA fold-back immunotoxins.
Please contact David Neville by phone
at 301–496–6807 or e-mail
davidn@mail.nih.gov for more
information.
Ribosomal Protein S3 (RPS3), an
Essential Component of NF-kB is a
Novel and Selective Drug Target
Description of Technology: NF-kB,
represented by the p50-p65
heterodimer, is a DNA binding protein
complex that has well documented
functions in inflammatory or
autoimmune diseases. Its potential as a
drug target is currently being explored
by the pharmaceutical industry.
The present invention describes that
ribosomal protein S3 (RPS3) is a novel
component of the p65 homodimer and
p65-p50 heterodimer DNA binding
complex. Experiments confirmed that
RPS3 is essential for normal expression
of specific NF-kB target genes, including
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
key physiological events that require
p65.
Advantages and Applications: A
novel and selective target for drug
candidates targeting the NF-kB pathway.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Michael J. Lenardo and
Fengyi Wan (NIAID).
Patent Status: U.S. Provisional
Application No. 60/913,336 filed 23 Apr
2007 (HHS Reference No. E–162–2007/
0–US–01).
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: Mojdeh Bahar, J.D.;
301–435–2950; baharm@mail.nih.gov.
Collaborative Research Opportunity:
The NIAID Laboratory of Immunology is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize this
technology. Please contact Dr. Michael
Lenardo at 301–496–6754 for more
information.
A New Technology for Identification of
Genes Expressed in Hypoxia Conditions
Description of Technology: Low
concentrations of oxygen (hypoxia) are
a major pathophysiological condition
conducive for angiogenesis, necessary
for tumor growth and metastasis of
cancer cells.
A new technology comprising of a
vector DNA (pGL2-TK-HRE) that
expresses the luciferase gene under the
influence of a hypoxia inducible
promoter sequence from the nitric oxide
synthase gene has been used to
transform various human tumor cell
lines such as U251–HRE and PC3–HRE.
These cells express little to no luciferase
under normal oxygen levels, but stably
express significantly higher levels under
low oxygen levels.
The transformed cell lines can be
used to screen and develop drugs and
small molecules that inhibit
angiogenesis, an attractive target for
cancer therapy. The technology can also
be used in gene therapy where the
therapeutic gene is being expressed
under a hypoxia inducible promoter.
Advantages: Quantitative; Robust,
stably express luciferase; Can be used in
vivo.
Applications: Early detection of
angiogenesis; Cancer therapeutics; Gene
therapy.
Market: Cancer is the second leading
cause of death in America, after heart
disease. Every year, more than a million
people are diagnosed with cancer. Over
50% of the cases reported in the U.S.
affect the lung, breast, prostate and
colorectal. Although the number of
E:\FR\FM\14FEN1.SGM
14FEN1
Federal Register / Vol. 73, No. 31 / Thursday, February 14, 2008 / Notices
deaths reported is declining 553,888
cancer deaths in 2004 compared to
556,902 in 2003, the total number of all
cancer deaths among women is rising.
With the help of the new technology
early detection, therapy and monitoring
of cancer combating efforts would be
possible.
Development Status: Developed.
Inventor: Giovanni Melillo (NCI)
Patent Status: HHS Reference No. E–
220–2003/0—Research Tool. Patent
protection is not being sought for this
technology.
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: John Stansberry,
PhD; 301/435–5236;
stansbej@mail.nih.gov.
Date: February 6, 2008.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–2752 Filed 2–13–08; 8:45 am]
Committee Name: Substance Abuse and
Mental Health Services Administration,
Center for Substance Abuse Prevention
National Advisory Council.
Date/Time/Type: March 6, 2008. From 9
a.m.–4:30 p.m.: Open.
Place: 1 Choke Cherry Road, Sugarloaf and
Seneca Conference Rooms, Rockville,
Maryland 20857.
Contact: Tia Haynes, Designated Federal
Official, SAMHSA/CSAP National Advisory
Council, 1 Choke Cherry Road, Room 4–1066,
Rockville, MD 20857, Telephone: (240) 276–
2436, Fax: (240) 276–2430, E-mail:
tia.haynes@samhsa.hhs.gov.
The accreditation and approval
of Amspec Services LLC, as commercial
gauger and laboratory became effective
on April 10, 2007. The next triennial
inspection date will be scheduled for
April 2010.
FOR FURTHER INFORMATION CONTACT:
Commercial Gauger Laboratory Program
Manager, Laboratories and Scientific
Services, U.S. Customs and Border
Protection, 1300 Pennsylvania Avenue,
NW., Suite 1500N, Washington, DC
20229, 202–344–1060.
Toian Vaughn,
Committee Management Officer, Substance
Abuse and Mental Health Services
Administration.
[FR Doc. E8–2715 Filed 2–13–08; 8:45 am]
Dated: January 31, 2008.
Ira S. Reese,
Executive Director, Laboratories and
Scientific Services.
[FR Doc. 08–678 Filed 2–13–08; 8:45 am]
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Accreditation and Approval of Amspec
Services LLC, as a Commercial Gauger
and Laboratory
Center for Substance Abuse
Prevention; Notice of Meeting
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of accreditation and
approval of Amspec Services LLC, as a
commercial gauger and laboratory.
Pursuant to Public Law 92–463,
notice is hereby given of the meeting of
the Center for Substance Abuse
Prevention (CSAP) National Advisory
Council on March 6, 2008.
The meeting is open and will include
discussion of the Center’s policy issues,
and current administrative, legislative
and program developments.
Attendance by the public will be
limited to space available. Public
comments are welcome. Please
communicate with the CSAP Council’s
Designated Federal Official, Ms. Tia
Haynes (see contact information below),
to make arrangements to attend,
comment or to request special
accommodations for persons with
disabilities.
Substantive program information, a
summary of the meeting, and a roster of
Council members may be obtained as
soon as possible after the meeting, either
by accessing the SAMHSA Committee
Web site, https://www.samhsa.gov/
council/csap/csapnac.aspx, or by
contacting Ms. Haynes. The transcript
for the open session will also be
available on the SAMHSA Council Web
site within three weeks after the
meeting.
SUMMARY: Notice is hereby given that,
pursuant to 19 CFR 151.12 and 19 CFR
151.13, Amspec Services LLC, 1818 A
Federal Road, Galena Park, TX 77015,
has been approved to gauge and
accredited to test petroleum and
petroleum products, organic chemicals
and vegetable oils for customs purposes,
in accordance with the provisions of 19
CFR 151.12 and 19 CFR 151.13. Anyone
wishing to employ this entity to conduct
laboratory analyses and gauger services
should request and receive written
assurances from the entity that it is
accredited or approved by the U.S.
Customs and Border Protection to
conduct the specific test or gauger
service requested. Alternatively,
inquiries regarding the specific test or
gauger service this entity is accredited
or approved to perform may be directed
to the U.S. Customs and Border
Protection by calling (202) 344–1060.
The inquiry may also be sent to
cbp.labhq@dhs.gov. Please reference the
Web site listed below for a complete
listing of CBP approved gaugers and
accredited laboratories. https://cbp.gov/
xp/cgov/import/operations_support/
labs_scientific_svcs/
commercial_gaugers/.
AGENCY:
rwilkins on PROD1PC63 with NOTICES
Substance Abuse and Mental Health
Services Administration
VerDate Aug<31>2005
16:49 Feb 13, 2008
Jkt 214001
PO 00000
Frm 00066
Fmt 4703
DATES:
BILLING CODE 9111–14–M
BILLING CODE 4162–20–P
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
8707
Sfmt 4703
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Accreditation and Approval of
Robinson International (USA) Inc., as a
Commercial Gauger and Laboratory
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: Notice of accreditation and
approval of Robinson International
(USA) Inc., as a commercial gauger and
laboratory.
AGENCY:
SUMMARY: Notice is hereby given that,
pursuant to 19 CFR 151.12 and 19 CFR
151.13, Robinson International (USA)
Inc., 4400 S. Wayside Drive, Suite 107,
Houston, TX 77207, has been approved
to gauge and accredited to test
petroleum and petroleum products,
organic chemicals and vegetable oils for
customs purposes, in accordance with
the provisions of 19 CFR 151.12 and 19
CFR 151.13. Anyone wishing to employ
this entity to conduct laboratory
analyses and gauger services should
request and receive written assurances
from the entity that it is accredited or
approved by the U.S. Customs and
Border Protection to conduct the
specific test or gauger service requested.
Alternatively, inquires regarding the
specific test or gauger service this entity
is accredited or approved to perform
may be directed to the U.S. Customs and
Border Protection by calling (202) 344–
1060. The inquiry may also be sent to
cbp.labhq@dhs.gov. Please reference the
Web site listed below for a complete
listing of CBP approved gaugers and
accredited laboratories.
https://cbp.gov/xp/cgov/import/
operations_support/labs_scientific_svcs/
commercial_gaugers/.
E:\FR\FM\14FEN1.SGM
14FEN1
]]>Agencies
[Federal Register Volume 73, Number 31 (Thursday, February 14, 2008)]
[Notices]
[Pages 8705-8707]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-2752]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
New Inhibitors of Multidrug Resistant Proteins Such as ABCG2
Description of Technology: Drug resistance plays a significant role
in the failure of cancer chemotherapy. Some proteins such as ABCG2, Pgp
and MRP1 that belong to the superfamily of ATP-binding cassette
transporters contribute to this process.
Two categories of ABCG2 protein inhibitors--botryllamides, isolated
from a marine sponge, and naphthopyrones, isolated from marine sea
stars--have been obtained by high-throughput screening of 89,000
natural product extracts from the Natural Products Repository at NCI.
These new compounds serve as potential therapeutic agents for
cancer chemotherapy either exclusively or in combination with
conventional regimens. The study of structure-activity relationships
will help delineate features that would enhance activity and
specificity to multiple drug resistant proteins.
Advantages: Increase bioavailability of orally administered drugs;
Enhance drug delivery to certain tissues.
Applications: Cancer therapeutics; Cancer stem cell research; Study
of structure, function and relevance of MDR in cancer.
Market: Cancer is the second leading cause of death in America,
after heart disease. Multiple drug resistance is a significant
impediment in the treatment of cancers resulting in poor prognosis.
Some cancers with demonstrated high levels of MDR are leukemia, colon,
renal, liver, adrenocortical, and pancreatic. Breast, ovarian, sarcoma
and small-cell lung cancer show increased MDR on treatment.
This new technology has the potential to increase the effectiveness
of conventional chemotherapy and prognosis of cancer.
Developmental Status: Early stage.
Inventors: Curtis J. Henrich et al. (NCI).
Patent Status: U.S. Provisional Application No. 60/018,758 filed 03
Jan 2008 (HHS Reference No. E-315-2007/0-US-01).
Licensing Status: Available for non-exclusive licensing.
Licensing Contact: John Stansberry, PhD; 301/435-5236;
stansbej@mail.nih.gov.
TGF-[beta] Gene Expression Signature in Cancer Prognosis
Description of Technology: Hepatocellular carcinoma (HCC) is the
third leading cause of cancer death worldwide, and it is very
heterogeneous in terms of its clinical presentation as well as genomic
and transcriptomic patterns. This heterogeneity and the lack of
appropriate biomarkers have hampered patient prognosis and treatment
stratification.
Available for licensing is a novel temporal TGF-[beta] gene
expression signature that predicts HCC patient clinical outcomes.
Patients with tumors expressing late TGF-[beta] responsive genes had a
malignant prognosis and an invasive tumor phenotype as evaluated by
decreased survival time, increased tumor recurrence, and vascular
invasion rate. Additionally, this signature may also be able to
prognose other cancers, including lung cancer.
Applications: Method to diagnose cancer; Method to monitor cancer
progression and aid clinicians to choose appropriate therapies;
Commercial kits to prognose cancer.
[[Page 8706]]
Advantages: Early diagnostic tool to stratify HCC patients to chose
more effective treatment.
Development Status: The technology is currently in the pre-clinical
stage of development.
Market:
An estimated 1,444,920 new cancer diagnoses in the U.S. in 2007.
Cancer is the second leading cause of death in United States.
It is estimated that the cancer therapeutic market would double to
$50 billion a year in 2010 from $25 billion in 2006.
Inventors: Snorri Thorgeirsson (NCI) and Cedric Coulouaran (NCI).
Relevant Publication: Manuscript in press Hepatology 2008.
Patent Status: U.S. Provisional Application No. 60/981,661 filed 22
Oct 2007 (HHS Reference No. E-282-2007/0-US-01).
Licensing Status: Available for exclusive or non-exclusive
licensing.
Licensing Contact: Jennifer Wong; 301-435-4633;
wongje@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute,
Center for Cancer Research, Laboratory of Experimental Carcinogenesis
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate, or
commercialize a novel temporal TGF-[beta] gene expression signature
that predicts HCC patient clinical outcomes. Please contact John D.
Hewes, PhD at 301-435-3121 or hewesj@mail.nih.gov for more information.
A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That
Can Increase Binding and Potency
Description of Technology: NIH inventors, in collaboration with
Scott and White Memorial Hospital inventors, have developed new
immunotoxins comprising a mutant diphtheria toxin linked to an anti-
prostate specific membrane antigen (PSMA) fold-back diabody. The fold-
back diabody construct has a shortened linker region between the heavy
and light chains of the antibody variable domain. This construct allows
interactions between the longer-linked variable domains while
preventing interactions between the shorter-linked variable domains.
This results in increased efficiency of epitope recognition and
delivery to the appropriate target cells. These immunotoxins can be
used for the treatment of cancers that overexpress PMSA, with specific
application against prostate cancer.
Applications:
Treatment of primary prostate tumors.
Treatment of metastatic prostate tumors, for which no currently
effective treatment exists.
Application against other tumors expressing the PSMA epitope on the
tumor neovasculature such as breast cancer.
Advantages:
Increased potency of 10-40-fold resulting from the use of the fold-
back diabody construct.
First treatment with applications to metastatic prostate cancer.
Pichia pastoris production process of the fold-back immunotoxin can
be used to scale up for GMP production.
Benefits:
Significant social benefit for successfully treating the second
leading cause of cancer-related deaths among males in the United
States.
Approximately 8 billion USD per year are spent on prostate cancer
treatment; a new treatment could procure a significant financial
position.
Opportunity to occupy a strong market position through the
development of the first treatment of metastatic prostate cancer.
Inventors: David Neville (NIMH) et al.
Patent Status: U.S. Patent Application No. 60/953,416 filed 01 Aug
2007 (HHS Reference No. E-268-2007/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: David A. Lambertson, PhD; 301-435-4632;
lambertsond@mail.nih.gov.
Collaborative Research Opportunity: The National Institute of
Mental Health, Laboratory of Molecular Biology, is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize anti-PSMA fold-
back immunotoxins. Please contact David Neville by phone at 301-496-
6807 or e-mail davidn@mail.nih.gov for more information.
Ribosomal Protein S3 (RPS3), an Essential Component of NF-kB is a Novel
and Selective Drug Target
Description of Technology: NF-kB, represented by the p50-p65
heterodimer, is a DNA binding protein complex that has well documented
functions in inflammatory or autoimmune diseases. Its potential as a
drug target is currently being explored by the pharmaceutical industry.
The present invention describes that ribosomal protein S3 (RPS3) is
a novel component of the p65 homodimer and p65-p50 heterodimer DNA
binding complex. Experiments confirmed that RPS3 is essential for
normal expression of specific NF-kB target genes, including key
physiological events that require p65.
Advantages and Applications: A novel and selective target for drug
candidates targeting the NF-kB pathway.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Michael J. Lenardo and Fengyi Wan (NIAID).
Patent Status: U.S. Provisional Application No. 60/913,336 filed 23
Apr 2007 (HHS Reference No. E-162-2007/0-US-01).
Licensing Status: Available for exclusive and non-exclusive
licensing.
Licensing Contact: Mojdeh Bahar, J.D.; 301-435-2950;
baharm@mail.nih.gov.
Collaborative Research Opportunity: The NIAID Laboratory of
Immunology is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize this technology. Please contact Dr. Michael Lenardo at
301-496-6754 for more information.
A New Technology for Identification of Genes Expressed in Hypoxia
Conditions
Description of Technology: Low concentrations of oxygen (hypoxia)
are a major pathophysiological condition conducive for angiogenesis,
necessary for tumor growth and metastasis of cancer cells.
A new technology comprising of a vector DNA (pGL2-TK-HRE) that
expresses the luciferase gene under the influence of a hypoxia
inducible promoter sequence from the nitric oxide synthase gene has
been used to transform various human tumor cell lines such as U251-HRE
and PC3-HRE. These cells express little to no luciferase under normal
oxygen levels, but stably express significantly higher levels under low
oxygen levels.
The transformed cell lines can be used to screen and develop drugs
and small molecules that inhibit angiogenesis, an attractive target for
cancer therapy. The technology can also be used in gene therapy where
the therapeutic gene is being expressed under a hypoxia inducible
promoter.
Advantages: Quantitative; Robust, stably express luciferase; Can be
used in vivo.
Applications: Early detection of angiogenesis; Cancer therapeutics;
Gene therapy.
Market: Cancer is the second leading cause of death in America,
after heart disease. Every year, more than a million people are
diagnosed with cancer. Over 50% of the cases reported in the U.S.
affect the lung, breast, prostate and colorectal. Although the number
of
[[Page 8707]]
deaths reported is declining 553,888 cancer deaths in 2004 compared to
556,902 in 2003, the total number of all cancer deaths among women is
rising.
With the help of the new technology early detection, therapy and
monitoring of cancer combating efforts would be possible.
Development Status: Developed.
Inventor: Giovanni Melillo (NCI)
Patent Status: HHS Reference No. E-220-2003/0--Research Tool.
Patent protection is not being sought for this technology.
Licensing Status: Available for non-exclusive licensing.
Licensing Contact: John Stansberry, PhD; 301/435-5236;
stansbej@mail.nih.gov.
Date: February 6, 2008.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-2752 Filed 2-13-08; 8:45 am]
BILLING CODE 4140-01-P
